Objective To explore the expression levels of ribonucleic acid(miR)-127-5p,miR-127 and miR-155 in elderly patients with pneumonia infection by multidrug-resistant bacteria and their correlation with immune-related cytokines.Methods 65 elderly patients with pneumonia infection by multidrug-resistant bacteria,80 healthy physical examination persons and 80 elderly patients with common pneumonia in our hospital from June 2020 to June 2022 were retrospectively selected as the observation group,the control group A and the control group B,respectively.The expression levels of miR-127-5p,miR-127,miR-155,interferon-γ(IFN-γ),interleu-kin(IL-4),IL-17,and transforming growth factor-β(TGF-β)in serum samples were detected and compared among the three groups.Pearson correlation analysis analyzed the correlation between miR-127-5p,miR-127,miR-155 and IFN-γ,IL-4,IL-17,TGF-β,and the Receiver operating characteristic curve(ROC)analyzed the diagnostic value of miR-127-5p,miR-127,miR-155 alone or in combination.Results The serum levels of miR-127-5p and IFN-γ in the control group B and the observation group were lower than those in the control group A,and the both in the observation group were lower than the both in the control group B(P<0.05).The serum levels of miR-127,miR-155,IL-4,IL-17,and TGF-β in the control group B and observation group were higher than those in the control group A,and those in the observation group were higher than those in the control group B(P<0.05).There was a positive correlation between serum miR-127-5p and serum IFN-γ levels(r=0.463,P<0.05),serum miR-127 and IL-4,IL-17 or TGF-β levels(r=0.306,0.273 or 0.330,P<0.05),and serum miR-155 and IL-4,IL-17 or TGF-β levels(r=0.410,0.453 or 0.385,P<0.05),and as well as a negative correlation between serum miR-127-5p and IL-4,IL-17 or TGF-β(r=-0.378,-0.396 or-0.408,P<0.05),serum miR-127 or miR-155 and IFN-γ levels(r=-0.267 or-0.513,P<0.05).Serum miR-127-5p,miR-127 and miR-155 expression levels alone and in combination have a certain diagnostic value in elderly patients with pneumonia infec-tion by multi-drug resistant bacteria,and the area under ROC curve(AUC)values were 0.811,0.733,0.817 and 0.906,and the sensitivities were 90.77%,60.00%,67.69%,84.62%,and the specificities were 66.87%,80.62%,83.75%,83.18%.Conclusion MiR-127-5p,miR-127 and miR-155 were differentially expressed in the elderly patients with pneumonia infection by multi-drug resistant bacteria,and were correlated with immune-related cytokines to a certain extent,and the combination of the three has a good diagnostic value,thus may providing a new target for clinical diagnosis of this disease.

Objective To explore the expression levels of ribonucleic acid(miR)-127-5p,miR-127 and miR-155 in elderly patients with pneumonia infection by multidrug-resistant bacteria and their correlation with immune-related cytokines.Methods 65 elderly patients with pneumonia infection by multidrug-resistant bacteria,80 healthy physical examination persons and 80 elderly patients with common pneumonia in our hospital from June 2020 to June 2022 were retrospectively selected as the observation group,the control group A and the control group B,respectively.The expression levels of miR-127-5p,miR-127,miR-155,interferon-γ(IFN-γ),interleu-kin(IL-4),IL-17,and transforming growth factor-β(TGF-β)in serum samples were detected and compared among the three groups.Pearson correlation analysis analyzed the correlation between miR-127-5p,miR-127,miR-155 and IFN-γ,IL-4,IL-17,TGF-β,and the Receiver operating characteristic curve(ROC)analyzed the diagnostic value of miR-127-5p,miR-127,miR-155 alone or in combination.Results The serum levels of miR-127-5p and IFN-γ in the control group B and the observation group were lower than those in the control group A,and the both in the observation group were lower than the both in the control group B(P<0.05).The serum levels of miR-127,miR-155,IL-4,IL-17,and TGF-β in the control group B and observation group were higher than those in the control group A,and those in the observation group were higher than those in the control group B(P<0.05).There was a positive correlation between serum miR-127-5p and serum IFN-γ levels(r=0.463,P<0.05),serum miR-127 and IL-4,IL-17 or TGF-β levels(r=0.306,0.273 or 0.330,P<0.05),and serum miR-155 and IL-4,IL-17 or TGF-β levels(r=0.410,0.453 or 0.385,P<0.05),and as well as a negative correlation between serum miR-127-5p and IL-4,IL-17 or TGF-β(r=-0.378,-0.396 or-0.408,P<0.05),serum miR-127 or miR-155 and IFN-γ levels(r=-0.267 or-0.513,P<0.05).Serum miR-127-5p,miR-127 and miR-155 expression levels alone and in combination have a certain diagnostic value in elderly patients with pneumonia infec-tion by multi-drug resistant bacteria,and the area under ROC curve(AUC)values were 0.811,0.733,0.817 and 0.906,and the sensitivities were 90.77%,60.00%,67.69%,84.62%,and the specificities were 66.87%,80.62%,83.75%,83.18%.Conclusion MiR-127-5p,miR-127 and miR-155 were differentially expressed in the elderly patients with pneumonia infection by multi-drug resistant bacteria,and were correlated with immune-related cytokines to a certain extent,and the combination of the three has a good diagnostic value,thus may providing a new target for clinical diagnosis of this disease.

BACKGROUND: Periodontitis is a severe chronic inflammatory disease, whose traditional systemic antimicrobial therapy faces great limitations. In-situ gels provide an effective solution as an emerging local drug delivery system. METHODS: In this study, the novel thermosensitive poloxamer/carbopol in-situ gels loaded with 20 lmol/L quercetin for the treatment of periodontitis were prepared by cold method. Thirteen batches of in-situ gels based on two independent factors (X1 : poloxamer 407 and X2 : carbopol 934P) were designed and optimized by the statistical method of central composite design (CCD). The transparency, pH, injectability, viscosity, gelation temperature, gelation time, elasticity modulus, degradation rate and in-vitro drug release studies of the batches were evaluated, and the percentage of drug release in the first hour, the time required for 90% drug release, gelation temperature, and gelation time were selected as dependent variables. RESULTS: These two independent factors significantly affected the four dependent variables (p < 0.05). The optimization result displayed that the optimized concentration of poloxamer 407 was 20.84% (w/v), and carbopol 934P was 0.5% (w/v). The optimized formulation showed a clear appearance (++), acceptable injectability (Pass), viscosity(151,798 mPa s), gelation temperature (36 °C), gelation time (213 s), preferable cell viability and cell proliferation, conformed to first-order release kinetics, and had a significant antibacterial effect. CONCLUSIONS The article demonstrates the great potential of the quercetin in-situ gel as an effective treatment for periodontitis.

BACKGROUND: Periodontitis is a severe chronic inflammatory disease, whose traditional systemic antimicrobial therapy faces great limitations. In-situ gels provide an effective solution as an emerging local drug delivery system. METHODS: In this study, the novel thermosensitive poloxamer/carbopol in-situ gels loaded with 20 lmol/L quercetin for the treatment of periodontitis were prepared by cold method. Thirteen batches of in-situ gels based on two independent factors (X1 : poloxamer 407 and X2 : carbopol 934P) were designed and optimized by the statistical method of central composite design (CCD). The transparency, pH, injectability, viscosity, gelation temperature, gelation time, elasticity modulus, degradation rate and in-vitro drug release studies of the batches were evaluated, and the percentage of drug release in the first hour, the time required for 90% drug release, gelation temperature, and gelation time were selected as dependent variables. RESULTS: These two independent factors significantly affected the four dependent variables (p < 0.05). The optimization result displayed that the optimized concentration of poloxamer 407 was 20.84% (w/v), and carbopol 934P was 0.5% (w/v). The optimized formulation showed a clear appearance (++), acceptable injectability (Pass), viscosity(151,798 mPa s), gelation temperature (36 °C), gelation time (213 s), preferable cell viability and cell proliferation, conformed to first-order release kinetics, and had a significant antibacterial effect. CONCLUSIONS The article demonstrates the great potential of the quercetin in-situ gel as an effective treatment for periodontitis.

BACKGROUND: Periodontitis is a severe chronic inflammatory disease, whose traditional systemic antimicrobial therapy faces great limitations. In-situ gels provide an effective solution as an emerging local drug delivery system. METHODS: In this study, the novel thermosensitive poloxamer/carbopol in-situ gels loaded with 20 lmol/L quercetin for the treatment of periodontitis were prepared by cold method. Thirteen batches of in-situ gels based on two independent factors (X1 : poloxamer 407 and X2 : carbopol 934P) were designed and optimized by the statistical method of central composite design (CCD). The transparency, pH, injectability, viscosity, gelation temperature, gelation time, elasticity modulus, degradation rate and in-vitro drug release studies of the batches were evaluated, and the percentage of drug release in the first hour, the time required for 90% drug release, gelation temperature, and gelation time were selected as dependent variables. RESULTS: These two independent factors significantly affected the four dependent variables (p < 0.05). The optimization result displayed that the optimized concentration of poloxamer 407 was 20.84% (w/v), and carbopol 934P was 0.5% (w/v). The optimized formulation showed a clear appearance (++), acceptable injectability (Pass), viscosity(151,798 mPa s), gelation temperature (36 °C), gelation time (213 s), preferable cell viability and cell proliferation, conformed to first-order release kinetics, and had a significant antibacterial effect. CONCLUSIONS The article demonstrates the great potential of the quercetin in-situ gel as an effective treatment for periodontitis.

Objective We tried to investigate the difference of respiratory symptoms,quality of life,blood routine examination and bone metabolism in patients with newly diagnosed chronic obstructive pulmonary disease with and without hypertension.Methods A total of 92 newly diagnosed patients with chronic obstructive pulmonary disease and hypertension treated in our hospital from January 2019 to April 2022 were selected as the observation group,and 92 newly diagnosed patients with COPD without hypertension were selected as the control group.The modified British Medical Research Council Respiratory Questionnaire(mMRC),Chronic Obstructive Pulmonary Disease Self Assessment Test Questionnaire(CAT),Global Initiative for Chronic Obstructive Pulmonary Disease(GOLD),SF-36 scale scores,blood routine examination and bone metabolism indexes were different.Results The rate of mMRC grade≥2 and CAT score of the observation group were significantly higher than those of the control group(P＜0.05),while the SF-36 score was significantly lower than that of the control group(P＜0.05).The GOLD grading of the observation group was significantly higher than that of the control group(P＜0.05).The forced vital capacity(FVC)and the first second expiratory volume(FEV1)in the observation group were significantly lower than those in the control group(P＜0.05).There was no significant difference between the observation group and the control group in white blood cell count(WBC),neutrophil count(NEUT)and lymphocyte count(LYM)etc(P＞0.05).The bone mineral density of the femoral neck and blood calcium in the observation group were signifi-cantly lower than those in the control group(P＜0.05),while the parathyroid hormone(PTH)and osteocalcin(BGP)were significantly higher than those in the control group(P＜0.05).The levels of C-reactive protein(CRP),procalcitonin(PCT),interleukin-6(IL-6),IL-4,and IL-10 in the observation group were significantly higher than those in the control group(P＜0.05).The hypertension grade in the observation group was positively correlated with mMRC grade,CAT score and GOLD grade(rs=0.455,0.302 and 0.501,P＜0.05),but negatively correlated with FVC and FEV1(rs=-0.311 and-0.334,P＜0.05).Conclusion The newly diagnosed patients with chronic obstructive pulmonary disease and hypertension have severe respiratory symptoms,poor quality of life,and an increased risk of osteoporosis,and the patient's blood pressure is related to the degree of respiratory symptoms.

Objective:To explore the correlation between high cholinergic pathway signaling and cognitive function in patients with Parkinson disease(PD) accompanied with sleep disorder.Methods:PD patients admitted from 2017 to 2022 were divided into PD with sleep disorder group (PD-SD group) ( n=56) and PD without sleep disorder group (PD-NSD group) ( n=41) according to the Parkinson's disease sleep scale (PDSS) score. All participants underwent magnetic resonance imaging examination.All patients were evaluated by the PDSS, Hoehn-Yahr (H-Y), Montreal cognitive assessment scale (MoCA), and cholinergic pathways hyper intensities scale (CHIPS). The difference of cognitive function between the two groups and the correlation between CHIPS and cognitive function were analyzed.Independent sample t-test, Spearman correlation analysis, and binary Logistic regression analysis were performed on the data by SPSS 26.0 statistical software. Results:(1)The MoCA score of the PD-SD group (22.00 (5.00)) was lower than that of the PD-NSD group (26.00 (5.00)) ( Z=-3.830, P<0.05). The total and all aspects scores of CHIPS in PD-SD group were higher than those in PD-NSD group(the total score of the low external capsule: 12.00(8.00), 0(8.00), the total score of the high external capsule: 12.00(2.00), 6.00(9.00), the total score of the radial crown: 8.00(0), 4.00(4.00), the total score of the centrum semiovale: 3.00(4.00), 0(2.00), the total score of the right side: 16.00(9.00), 5.00(10.00), the total score of the left side: 17.00(6.00), 7.00(9.00), the total score of CHIPS: 32.00(14.00), 14.00(20.00))( Z=-5.081, -5.873, -4.933, -3.211, -5.562, -6.232, -5.995, all P<0.05). (2)The correlation analysis between the score of CHIPS and cognitive function in the PD-SD group showed that, the total score of the low external capsule ( r=-0.286), the total score of the centrum semiovale ( r=-0.307), the total score of the right side ( r=-0.376), the total score of the left side ( r=-0.284) and the total score of CHIPS ( r=-0.349) were negatively correlated with MoCA(all P<0.05). (3)Binary Logistic regression analysis showed that white matter lesions in centrum semiovale, low inner capsule, right and left leukodystrophy were not influence factors for cognitive impairment (all P>0.05). Conclusion:PD patients with sleep disorders have lower cognitive function scores, higher CHIPS scores, and significant changes in white matter lesions compared to those without sleep disorders. In PD patients with sleep disorders, the higher the CHIPS score, the lower the cognitive function score, and the more significant the rate of cognitive impairment occurrence and development.

BACKGROUND: Periodontitis is a severe chronic inflammatory disease, whose traditional systemic antimicrobial therapy faces great limitations. In-situ gels provide an effective solution as an emerging local drug delivery system. METHODS: In this study, the novel thermosensitive poloxamer/carbopol in-situ gels loaded with 20 lmol/L quercetin for the treatment of periodontitis were prepared by cold method. Thirteen batches of in-situ gels based on two independent factors (X1 : poloxamer 407 and X2 : carbopol 934P) were designed and optimized by the statistical method of central composite design (CCD). The transparency, pH, injectability, viscosity, gelation temperature, gelation time, elasticity modulus, degradation rate and in-vitro drug release studies of the batches were evaluated, and the percentage of drug release in the first hour, the time required for 90% drug release, gelation temperature, and gelation time were selected as dependent variables. RESULTS: These two independent factors significantly affected the four dependent variables (p < 0.05). The optimization result displayed that the optimized concentration of poloxamer 407 was 20.84% (w/v), and carbopol 934P was 0.5% (w/v). The optimized formulation showed a clear appearance (++), acceptable injectability (Pass), viscosity(151,798 mPa s), gelation temperature (36 °C), gelation time (213 s), preferable cell viability and cell proliferation, conformed to first-order release kinetics, and had a significant antibacterial effect. CONCLUSIONS The article demonstrates the great potential of the quercetin in-situ gel as an effective treatment for periodontitis.

BACKGROUND: Periodontitis is a severe chronic inflammatory disease, whose traditional systemic antimicrobial therapy faces great limitations. In-situ gels provide an effective solution as an emerging local drug delivery system. METHODS: In this study, the novel thermosensitive poloxamer/carbopol in-situ gels loaded with 20 lmol/L quercetin for the treatment of periodontitis were prepared by cold method. Thirteen batches of in-situ gels based on two independent factors (X1 : poloxamer 407 and X2 : carbopol 934P) were designed and optimized by the statistical method of central composite design (CCD). The transparency, pH, injectability, viscosity, gelation temperature, gelation time, elasticity modulus, degradation rate and in-vitro drug release studies of the batches were evaluated, and the percentage of drug release in the first hour, the time required for 90% drug release, gelation temperature, and gelation time were selected as dependent variables. RESULTS: These two independent factors significantly affected the four dependent variables (p < 0.05). The optimization result displayed that the optimized concentration of poloxamer 407 was 20.84% (w/v), and carbopol 934P was 0.5% (w/v). The optimized formulation showed a clear appearance (++), acceptable injectability (Pass), viscosity(151,798 mPa s), gelation temperature (36 °C), gelation time (213 s), preferable cell viability and cell proliferation, conformed to first-order release kinetics, and had a significant antibacterial effect. CONCLUSIONS The article demonstrates the great potential of the quercetin in-situ gel as an effective treatment for periodontitis.

Objective:To compare the efficacy and safety of different dosages of new drugs in the treatment of PsA by using network meta-analysis.Methods:Three medical databases (PubMed, Web of Science, Cochrane Library) were searched for the studies that compared the efficacy and safety of 4 new drugs (secukinumab, ixekizumab, apremilast, tofacitinib) with different dosages in the treatment of PsA. Data from included studies were analyzed by Stata 15.0.Results:A total of 16 RCTs were included. The results of the network meta-analysis showed that: (1) Among the overall patients, in terms of ACR20 response rate, the larger the surface under the cumulative ranking (SUCRA), the more effective it is. Secukinumab 300 mg Q4W(96.1%) had the best efficacy, followed by ixekizumab 80 mg Q4W(79.0%), ixekizumab 80 mg Q2W(75.1%), secukinumab 150 mg Q4W(73.2%), apremilast 30 mg BID(50.6%), apremilast 20 mg BID(38.6%), tofacitinib 5 mg BID(18.1%), tofacitinib 10 mg BID(17.7%) and placebo(2.0%). (2) In terms of PASI75 response rate, the larger the area under the SUCRA curve, the more effective it is. Ixekizumab 80 mg Q4W(96.1%) had the best efficacy, followed by ixekizumab 80 mg Q2W(88.7%), secukinumab 300 mg Q4W(75.6%), secukinumab 150 mg Q4W(63.3%), apremilast 30 mg BID(44.5%), apremilast 20 mg BID(38.4%), tofacitinib 10 mg BID(30.0%), tofacitinib 5 mg BID(12.5%) and placebo(1.0%). (3) Among the overall patients, in terms of safety, the smaller the area under the SUCRA curve, the higher the safety it is. Secukinumab 300 mg Q4W (17.3%) has the best safety. (4) The results of subgroup analysis showed that in terms of ACR20 response rate, ixekizumab 80 mg Q2W(85.3%) had the best efficacy in bDMARDs-na?ve patients, while in bDMARDs-IR patients, secukinumab 300 mg Q4W(83.9%) had the best efficacy.Conclusion:Among all patients, secukinumab 300 mg Q4W is the best in terms of ACR20 response rate and safety, but ixekizumab 80 mg Q4W is more effective in improving PsA lesions comparing yo other drugs.